CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
U-Systems, Inc.
ClinicalTrials.gov Identifier:
NCT01424956
First received: August 25, 2011
Last updated: April 16, 2013
Last verified: April 2013
  Purpose

To determine the impact on Interpreting Physician performance in detecting breast cancer, as defined by the area under the Receiver Operating Characteristic Curve (ROC), when Automated Breast Ultrasound (ABUS) and screening mammography (XRM) are combined, compared to screening mammography alone in asymptomatic women with >50% parenchymal density and a screening mammogram assigned a BI-RADS Assessment Category 1 (negative) or 2 (normal with benign findings).

The effect of the improved Reader performance is illustrated by plotting the ROC curves for XRM alone and XRM+ABUS. If Reader performance improves with the addition of ABUS to the XRM, the area under the curve (AUC) for XRM+ABUS (AUCXRM+ABUS) will be greater than the area under the curve for XRM Alone (AUCXRM Alone). This difference is represented as ∆AUCABUS. The null and alternative hypotheses can be formally expressed as follows:

H0: ∆AUCABUS = 0, AUCXRM+ABUS = AUCXRM Alone The null hypothesis is that Reader performance will be unchanged with the addition of ABUS to a screening mammogram assigned a BI-RADS Assessment Category of 1 or 2.

HA: ∆AUCABUS ≠ 0, AUCXRM+ABUS ≠ AUCXRM Alone The alternative hypothesis is that Reader performance will be changed with the addition of ABUS to a screening mammogram assigned a BI-RADS Assessment Category of 1 or 2. A statistically significant change will be considered equivalent to a statistically significant improvement if the estimated value of AUCXRM+ABUS is greater than that of AUCXRM Alone with statistical significance at an alpha level of .05 for a two-sided test.


Condition Intervention
Breast Cancer
Device: Automated Breast Ultrasound (ABUS)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: To Determine the Impact on Reader Performance, as Defined by the Area Under the Receiver Operating Characteristic Curve, When Automated Breast Ultrasound and a Screening Mammogram Are Combined, Compared to a Screening Mammogram Alone in Asymptomatic Women With >50% Parenchymal Density and a Screening Mammogram Assigned a BI-RADS Assessment Category 1 (Negative) or 2 (Normal With Benign Findings).

Resource links provided by NLM:


Further study details as provided by U-Systems, Inc.:

Primary Outcome Measures:
  • Interpreting Physician Performance In Detecting Breast Cancer [ Time Frame: Two months ] [ Designated as safety issue: No ]
    To determine the impact on Interpreting Physician (Reader) Performance in detecting breast cancer, as defined by the area under the Receiver Operating Characteristic (ROC) Curve (AUC), when ABUS and XRM are combined (XRM+ABUS), compared to XRM Alone in asymptomatic women with >50% parenchymal density (BI-RADS Composition/Density rating of 3 or 4) and a screening mammogram assigned a BI-RADS Assessment Category 1 (negative) or 2 (normal with benign findings).


Secondary Outcome Measures:
  • Interpreting Physician sensitivity and specificity of breast cancer detection. [ Time Frame: Two months ] [ Designated as safety issue: No ]
    Reader sensitivity and specificity when XRM+ABUS are combined compared to XRM Alone for two different combinations of cut points.


Enrollment: 17
Study Start Date: July 2011
Study Completion Date: September 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Asymptomatic Women who have Dense Breast Tissue
Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
Device: Automated Breast Ultrasound (ABUS)
Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
Other Names:
  • somo.V ABUS
  • ABUS
  • Whole Breast Ultrasound

Detailed Description:

The Clinical Retrospective Reader Study is an observational case-controlled, multi-reader multi-case Receiver Operating Characteristic (ROC) study involving approximately 16 Interpreting Physicians (Readers) and approximately 200 breast screening cases which will be reviewed and of those, 164 breast screening cases will be included in the primary data analysis. All primary data analysis cases will consist of screening mammogram and Automated Breast Ultrasound image readings from the same asymptomatic females with >50% parenchymal density for whom the screening mammogram was assigned a BI-RADS Assessment Category 1 (negative) or 2 (normal with benign findings).

The Readers will review a total of 200 cases: the Non-Cancer Case Set, the Cancer Case Set, and additional Control and Supplemental Case Sets. These cases will be randomized during the reading session so each Reader will review the entire Case Set in a unique order.

The primary Receiver Operating Characteristic analysis will be performed on the Readers' Likelihood of Malignancy (LOM) ratings from their initial review of the screening mammogram alone and their final review of the screening mammogram and Automated Breast Ultrasound for the Non-Cancer Case Set and Cancer Case Set.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

17 Interpreting Physicians (Readers) qualified by training and experience, who are in breast imaging practices in the United States.

Criteria

Inclusion Criteria:

  • Interpreting Physician as defined under 21CFR §900.12(a)(1)(i)(B)(2).
  • Fellowship-Trained in Breast Imaging and or have 10 years experience in breast imaging in which the radiologist's practice was at least 70% breast imaging
  • Currently meets the minimum Mammography Interpretation requirements per MQSA
  • Review Rate of at least 1,000 Mammograms annually for the year prior to study participation
  • Review Rate of at least 500 Breast Ultrasounds annually for the year prior to study participation
  • Successful completion of ABUS training

Exclusion Criteria:

  • Does not meet definition of Interpreting Physician as defined under 21CFR §900.12(a)(1)(i)(B)(2).
  • Does not meet requirements of Fellowship-Trained in Breast Imaging and or have 10 years experience in breast imaging in which the radiologist's practice was at least 70% breast imaging
  • Does not meet requirements of minimum Mammography Interpretation requirements per MQSA
  • Does not meet requirements of Review Rate of at least 1,000 Mammograms annually for the year prior to study participation
  • Does not meet requirements of Review Rate of at least 500 Breast Ultrasounds annually for the year prior to study participation
  • Does not meet requirements of successful completion of ABUS training
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01424956

Locations
United States, California
U-Systems, Inc.
Sunnyvale, California, United States, 94085
Sponsors and Collaborators
U-Systems, Inc.
Investigators
Principal Investigator: Maryellen Giger, Ph.D. University of Chicago, Department of Radiology
  More Information

No publications provided

Responsible Party: U-Systems, Inc.
ClinicalTrials.gov Identifier: NCT01424956     History of Changes
Other Study ID Numbers: USI2011001
Study First Received: August 25, 2011
Last Updated: April 16, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by U-Systems, Inc.:
breast
breast cancer
breast screening
breast cancer screening
ultrasound
ultrasonography
mammogram
mammography
breast density
dense breasts
early detection
somo v
somo•v
U-Systems
Automated Breast Ultrasound
Ultrasonography, Mammary
Breast Neoplasms
Breast Density > 50% (BI-RADS III & IV)

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 18, 2014